Short-term efficacy and safety analysis of subcutaneous immunotherapy for children with allergic rhinitis
10.16066/j.1672-7002.2025.01.006
- VernacularTitle:皮下免疫治疗儿童变应性鼻炎的早期疗效与安全性分析
- Author:
Yuqin HU
1
;
Lihua MO
;
Xiancheng WANG
;
Min ZHI
;
Jianwen ZHONG
;
Dabo LIU
;
Xiangqian LUO
Author Information
1. 南方医科大学深圳医院儿童耳鼻咽喉科,广东 深圳 518101
- Keywords:
Rhinitis,Allergic,Perennial;
Child;
Immunotherapy;
Treatment Outcome;
Drug-Related Side Effects and Adverse Reactions;
subcutaneous immunotherapy;
short-term efficacy
- From:
Chinese Archives of Otolaryngology-Head and Neck Surgery
2025;32(1):27-32
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the short-term efficacy,safety and related influencing factors of subcutaneous immunotherapy(SCIT)in children with allergic rhinitis(AR).METHODS Retrospective analyzed the clinical data of 147 children with AR who underwent SCIT at Shenzhen Hospital of Southern Medical University from August 2020 to May 2024.The clinical characteristics and laboratory parameters were collected,the visual analogue scale(VAS),total symptom score(TSS),total medication score(TMS)and combined symptom medication score(CSMS)were compared at the baseline and 3,6 and 12 months after treatment.The incidence of local adverse reactions(LRs)and systemic adverse reactions(SRs)during treatment was also documented.RESULTS A total of 147 children with AR aged 5-18 years were included in the study.A significant reduction was observed in VAS,TSS,TMS and CSMS at months 3,6 and 12 of follow up compared with baseline(all P<0.001),and the short-term onset time was months 3 after treatment.The level of VitD3 in the effective group was significantly higher than that in the ineffective group(P<0.001).Serum VitD3 level was negatively correlated with clinical symptom(R=-0.3,P=0.026).The total number of injections in 147 children was 3201.LRs occurred in 52 children(35.4％),the number of injections was 69(2.2％).SRs occurred in 21 children(14.3％),and the number of injections was 34(1.1％).No grade Ⅲ or Ⅳ SRs occurred.In the logistic regression analysis,body mass index(BMI)was a risk factor for LRs(OR:2.220,95％CI:1.009-4.887,P=0.048).CONCLUSION SCIT demonstrates significant early efficacy and a favorable safety profile safety in children with AR.Serum Vitamin D3 deficiency can affect the short-term efficacy of SCIT.Overweight and obese children are prone to develop local adverse reactions.
